|Articles|September 20, 2018

OmniComm’s TrialMaster EDC Selected by Sorrento Therapeutics for Cancer Research

Sorrento Therapeutics, Inc., a clinical stage, antibody-centric, biopharmaceutical company, has signed a new agreement with OmniComm Systems, Inc., a global provider of clinical data management technology, in which they will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple Sorrento research sites.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

ByMarcela Roy, MA, Lauren Crooks, MSc, Graham Ellis, MD, Alan Kott, MUDR, Dawie Wessels, MD, Elias Ketiar, MD, MRCP

June 4th 2026

For pharmaceutical and life sciences organizations, the strategic imperative is clear: begin immediately with foundation building, scale systematically with measurable milestones, and transform comprehensively toward AI-native data operations. Credit: Stock.Adobe.com/tippapatt.

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

ByPartha Anbil,Partha Khot

June 4th 2026

OmniComm’s TrialMaster EDC Selected by Sorrento Therapeutics for Cancer Research

Related Content

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

A Shot in the Arm to Traditional Vaccine Trial Strategy

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention